Carboplatin + PLD + Bevacizumab (platinum-sensitive recurrent ovarian)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CARBOPLATIN DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN DRUG-BEVACIZUMAB |
|---|
| ID | REG-CARBO-PLD-BEV-OVARIAN |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-GOG0213-COLEMAN-2017 SRC-NCCN-OVARIAN-2025 |
Notes
Carbo+PLD+bev is the platinum-sensitive recurrence backbone preferred in patients with residual peripheral neuropathy from prior taxane exposure (PLD substitutes for paclitaxel). Direct carbo+PLD+bev RCT evidence is extrapolated from GOG-0213 (carbo+pacli+bev) plus the separate carbo+PLD vs carbo+pacli equivalence (CALYPSO, Pujade-Lauraine JCO 2010 — comparable PFS, distinct toxicity profile favoring PLD for neuropathy). Lower bev dose (10 mg/kg q14d) per OCEANS-style schedule; alternative 15 mg/kg q21d acceptable.
Used By
Indication
IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV- IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV